Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.

被引：0
|
作者：
Li, Jinpeng
Chen, Hua
Song, Jinlong
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Intervent Ward One, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16134
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
    Ye, Shuang
    Fu, Yi
    Liu, Shuai
    Wang, Jun
    Zhou, Lin
    Jiang, Wei
    Pei, Xuan
    Shen, Wenbin
    Sun, Min
    Shan, Boer
    Yang, Huijuan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A262 - A263
  • [42] Efficacy of Shipixiaoji Granules, Lenvatinib, and Tislelizumab in Patients with Unresectable Hepatocellular Carcinoma: Protocol for a Prospective, Single-Arm, Phase II Trial
    Zhang, Zhen
    Liang, Zicheng
    Tan, Xiaoning
    Jian, Huiying
    Gao, Wenhui
    Zeng, Puhua
    NATURAL PRODUCT COMMUNICATIONS, 2024, 19 (12)
  • [43] Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial
    Nong, Xiang
    Zhang, Yu-Mei
    Liang, Jing-Chang
    Xie, Jin-Long
    Zhang, Zhi-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Prospective phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Efficacy analysis
    Geschwind, Jean-Francois
    Feng, Allen
    Reyes, Diane K.
    Kamel, Ihab R.
    Halappa, Vivek Gowdra
    Corona-Villalobos, Celia Pamela
    Cosgrove, David
    Pawlik, Timothy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Prospective phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Efficacy analysis
    Feng, Allen
    Reyes, Diane K.
    Kamel, Ihab R.
    Halappa, Vivek Gowdra
    Corona-Villalobos, Celia
    Cosgrove, David
    Bhagat, Nikhil
    Hebert, Jillyn
    Wahlin, Tamara
    Foltz, Jessica
    Pawlik, Timothy M.
    Geschwind, Jean-Francois H.
    HEPATOLOGY, 2012, 56 (06) : 1535 - 1535
  • [46] Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results
    Cosgrove, David P.
    Reyes, Diane K.
    Pawlik, Timothy M.
    Feng, Allen L.
    Kamel, Ihab R.
    Geschwind, Jean-Francois H.
    RADIOLOGY, 2015, 277 (02) : 594 - 603
  • [47] Hepatic artery infusion chemotherapy combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma presenting portal vein tumor thrombus: A prospective, single-arm study
    He, Qiang
    Wu, Chenrui
    Pan, Long
    Li, Jiachu
    Zhou, Yin
    Cao, Hongxiang
    Sun, Ruirui
    Huang, Junjie
    Wang, Yongchen
    Huang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Camrelizumab in combination with TACE for the treatment of unresectable hepatocellular carcinoma (HCC): A multicenter, single-arm, prospective real-world study.
    You, Ran
    Yin, Guowen
    Xu, Hao
    Zhu, Xiaoli
    Zhang, Qingqiao
    Wang, Qi
    Cao, Chi
    Lu, You
    Jiang, Hao
    Liu, Jun
    Yu, Hui
    Xu, Qingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
    Wang, Miao
    Zhou, Jiamin
    Xu, Weiqi
    Pan, Qi
    Mao, Anrong
    Zhang, Ning
    Feng, Yun
    He, Xigan
    Lin, Zhenhai
    Wang, Longrong
    Zhang, Yongfa
    Zhu, Hongxu
    Ding, Zhiwe
    Wang, Yixiu
    Yu, Bingran
    Zhang, Ti
    Wang, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 489 - 489
  • [50] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Wang, Huaying
    Shen, Wenbin
    Shan, Boer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345